INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 12, 2016 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 12,713 | $368.70 | 550,851 |
| Jun 25, 2004 |
Director
Trans History: 742
|
Director | Form 4 | Bona fide gift | 20,870 | -- | 551,715 |
| Aug 26, 2014 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 303,909 | $11.64 | 552,449 |
| Jul 09, 2018 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 153,274 | $16.80 | 553,121 |
| Jun 20, 2018 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 153,274 | $16.80 | 553,121 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,629 | $573.47 | 553,511 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 10,270 | $472.56 | 554,718 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 5,723 | $572.43 | 556,140 |
| Jun 18, 2010 |
Director
Trans History: 742
|
Director | Form 4 | Other acquisition or disposition (describe transaction) | 31,761 | -- | 560,512 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 7,800 | $571.41 | 561,863 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.